Published in Eur J Nucl Med Mol Imaging on February 01, 2012
Comment on Pepe et al.: somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 1.39
Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol Pharm (2014) 0.78
Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging (2015) 0.78
Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept (2013) 0.77
Reply to comment on Pepe et al.: Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 0.75
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 7.47
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med (1993) 3.45
Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP (2008) 3.31
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med (2000) 3.26
Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev (2003) 2.92
Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med (1990) 2.85
Octreotide. N Engl J Med (1996) 2.67
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev (1991) 2.20
Imaging of neuroendocrine tumors. Semin Nucl Med (2006) 2.01
Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med (1999) 1.92
Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci (1995) 1.90
99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med (2000) 1.83
A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest (2000) 1.80
Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP (1987) 1.77
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer (2010) 1.76
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76
Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP (1998) 1.74
Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med (1992) 1.54
Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res (1994) 1.53
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging (2003) 1.46
Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging (2003) 1.45
The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol (2006) 1.44
Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med (1998) 1.43
Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med (1994) 1.42
Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med (1998) 1.41
Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med (1993) 1.24
Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM (1998) 1.23
All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun (1994) 1.22
SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) (2003) 1.22
Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med (1993) 1.20
Somatostatin receptor imaging. Semin Nucl Med (2002) 1.18
In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med (2002) 1.16
Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med (1997) 1.15
Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol (2008) 1.15
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res (1998) 1.13
Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res (2005) 1.12
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol (2005) 1.11
Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab (2003) 1.11
Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut (1996) 1.10
Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg (2000) 1.09
Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med (1994) 1.07
Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg (1994) 1.07
Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut (1994) 1.04
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 1.03
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med (2000) 1.02
Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med (1996) 1.02
Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion (1996) 1.00
Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg (1997) 0.99
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med (1998) 0.99
Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection. Ann ICRP (1991) 0.99
Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol (2002) 0.98
In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab (1993) 0.98
MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J Nucl Med (2005) 0.97
Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet (1984) 0.96
Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res (1994) 0.96
Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med (2003) 0.95
Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging (2005) 0.94
Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging (2008) 0.90
Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med (1995) 0.89
Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med (1998) 0.89
Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med (1994) 0.89
The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med (1994) 0.88
Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging (2004) 0.87
Functional-anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm (2004) 0.85
[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging (2002) 0.85
Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med (2002) 0.84
Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res (1997) 0.84
Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion (1996) 0.83
Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol (1993) 0.83
Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features. Lab Invest (1995) 0.83
Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med (2000) 0.82
Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med (2002) 0.82
Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2002) 0.82
Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med (1995) 0.82
Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med (1998) 0.82
111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med (2000) 0.81
Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) (1995) 0.81
Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol (2004) 0.80
Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest (2001) 0.80
99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging (2003) 0.79
Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Clin Nucl Med (2009) 0.78
Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res (1995) 0.78
Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer (1994) 0.77
Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J Pharmacol Exp Ther (1993) 0.77
[99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Cancer Biother Radiopharm (2011) 0.77
Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med (1994) 0.77
[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab (1994) 0.76
Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT. Nucl Med Commun (2007) 0.76
Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm (2001) 0.75
[123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Eur J Nucl Med Mol Imaging (2005) 0.75
Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. Br J Haematol (2001) 0.75
Visualisation of the normal adrenals at SPET examination with 111In-pentetreotide. Eur J Nucl Med Mol Imaging (2003) 0.75
Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest (1999) 0.75
Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy. Rev Esp Med Nucl (2005) 0.75
Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol (1996) 0.75
Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer (1995) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med (2015) 2.93
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (2013) 2.30
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol (2006) 1.75
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging (2010) 1.68
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol (2008) 1.54
Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging (2003) 1.45
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. Br J Haematol (2003) 1.44
Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a retrospective study. BMC Endocr Disord (2008) 1.41
EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med (2013) 1.37
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging (2008) 1.33
Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther (2003) 1.33
Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging (2007) 1.30
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer. Eur J Nucl Med Mol Imaging (2004) 1.25
Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev (2007) 1.21
An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med (2003) 1.18
EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging (2008) 1.18
In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med (2002) 1.16
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol (2006) 1.12
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 1.03
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol (2009) 1.00
Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 1.00
FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging (2008) 1.00
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica (2012) 1.00
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother (2005) 1.00
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 0.99
Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging (2008) 0.99
A portrait of the scientist as a young woman : comments after the first EANM Young Investigators' meeting. Eur J Nucl Med Mol Imaging (2009) 0.97
131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.96
Surgical procedures in the DANTE trial, a randomized study of lung cancer early detection with spiral computed tomography: comparative analysis in the screening and control arm. J Thorac Oncol (2011) 0.96
Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging (2005) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm (2004) 0.93
Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol (2010) 0.92
FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.92
67Ga scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.92
FDG PET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging (2012) 0.91
Workshop report: clinical diagnosis and imaging of sacroiliitis, Innsbruck, Austria, October 9, 2003. J Rheumatol (2004) 0.91
Diagnostic accuracy of basal TSH determinations based on the intravenous TRH stimulation test: an evaluation of 2570 tests and comparison with the literature. BMC Endocr Disord (2007) 0.90
Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol (2013) 0.90
18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med (2012) 0.89
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.87
Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun (2004) 0.87
Molecular imaging in radiotherapy planning for head and neck tumors. J Nucl Med (2011) 0.86
FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.86
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med (2012) 0.86
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer (2008) 0.86
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm (2007) 0.85
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol (2009) 0.84
Diagnostic and therapeutic aspects of iatrogenic hypoparathyroidism. Tumori (2004) 0.84
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging (2007) 0.83
Breast scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.83
Gastric carcinoid type I tumour: new diagnostic and therapeutic method. Eur J Gastroenterol Hepatol (2003) 0.83
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.82
Reference values for thyrotropin. Thyroid (2005) 0.82
F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib. Clin Nucl Med (2005) 0.81
Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report. Strahlenther Onkol (2003) 0.81
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. Int J Radiat Oncol Biol Phys (2007) 0.81
Metastatic gastric cancer presenting with shoulder-hand syndrome: a case report. J Med Case Rep (2008) 0.81
Imaging biomarkers in primary brain tumours. Eur J Nucl Med Mol Imaging (2014) 0.80
Simple preparation and purification of ethanol-free solutions of 3'-deoxy-3'-[18F]fluorothymidine by means of disposable solid-phase extraction cartridges. Nucl Med Biol (2011) 0.80
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur (2007) 0.80
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging (2006) 0.80
Evaluation of circulating calcitonin: analytical aspects. Tumori (2004) 0.80
Computed axial tomography-MIBI image fusion for preoperative localization in primary hyperparathyroidism. Am J Surg (2004) 0.80
Nutritional treatment of incipient thyroid autoimmune disease. Influence of selenium supplementation on thyroid function and morphology in children and young adults. Clin Nutr (2005) 0.80
Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2009) 0.80
Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori (2015) 0.79
Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or =2 cm. Endocr Relat Cancer (2008) 0.79
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. Anticancer Res (2003) 0.79
PET in radiotherapy planning: particularly exquisite test or pending and experimental tool? Radiother Oncol (2010) 0.79
[11C]-choline PET/CT in imaging locally advanced prostate cancer. Nucl Med Rev Cent East Eur (2011) 0.79
99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging (2003) 0.79
Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging (2011) 0.79
Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J Nucl Med (2011) 0.79
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging (2014) 0.79
The role of radionuclide therapy in medullary thyroid cancer. Tumori (2004) 0.78
What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients? Acta Oncol (2014) 0.78
99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging (2003) 0.78
Cardiac and acoustic metastases in relapsing melanoma. Clin Nucl Med (2013) 0.78
Accuracy of preoperative pinhole subtraction single photon emission computed tomography for patients with primary and recurrent hyperparathyroidism in an endemic goiter area. Surg Today (2004) 0.78
What impact can fluorine-18 fluorodeoxyglucose PET/computed tomography have on HIV/AIDS and tuberculosis pandemic? Nucl Med Commun (2009) 0.78
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology (2013) 0.78
Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. J Pathol (2003) 0.78
Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study. Med Sci Monit (2012) 0.78
Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide. Eur J Endocrinol (2003) 0.78
Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings. Microvasc Res (2010) 0.78
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient. J Cancer Res Clin Oncol (2013) 0.77
Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer (2006) 0.77
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Eur J Nucl Med Mol Imaging (2012) 0.77
Images in cardiovascular medicine. Generalized large vessel arteritis visualized by 18fluorodeoxyglucose-positron emission tomography. Circulation (2003) 0.77
Feasibility of carbidopa premedication in pediatric patients: a pilot study. Cancer Biother Radiopharm (2012) 0.77